Last reviewed · How we verify
Norepinephrine, dopamine
At a glance
| Generic name | Norepinephrine, dopamine |
|---|---|
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Laboratory Evaluation of Chronic Autonomic Failure
- Diagnosis of Pheochromocytoma (PHASE1)
- Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol (PHASE3)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) (PHASE3)
- Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) (PHASE4)
- Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock (PHASE4)
- Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |